Cadonilimab plus standard therapy to preserve bladder or kidney function
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of the immunotherapy drug cadonilimab (AK104) plus standard treatment to try to preserve bladder or kidney function in people with high-risk urothelial or kidney cancer. It is for patients who have not had prior systemic therapy and who want to avoid losing their entire bladder or kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with urothelial carcinoma (bladder cancer) or renal cell carcinoma (kidney cancer).
- You have not received any prior chemotherapy, immunotherapy, or other systemic cancer treatment.
- Your cancer is high-risk but has not spread to distant organs (stage 2 or higher, or with lymph node involvement).
- You are willing to have surgery, but the goal is to preserve as much of your bladder or kidney function as possible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Hear when a new Urinary System Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.